搜索
>产品 > FGL1蛋白

FGL1蛋白:LAG-3免疫治疗新配体

背景
FGL1是纤维蛋白原蛋白质家族的成员。正常情况下,FGL1在肝脏低水平表达,但在前列腺癌、黑素瘤等许多类型的癌症中均高表达。最新研究表明,FGL1是LAG-3的主要配体并具有高亲和力,表明FGL1的发现将开启肿瘤免疫治疗新时代,为肿瘤的免疫治疗提供新契机。
为满足市场需求,ACROBiosystems开发了由HEK293表达的多种属(Human, Mouse, Cyno)和多种标签(Fc, His)的FGL1重组蛋白,更有AviTagTM生物素标记的FGL1蛋白可以助力于您的药物开发。ACRO对FGL1蛋白的纯度、活性等性能进行了验证,并可免费提供相应的Protocol。
应用
FGL1产品列表(HEK293表达)
Molecule Cat. No. Host Product Description
FGL1
(HEK293表达)
FG1-H52Hy Human FGL1 Protein, His Tag
FG1-H5258 Human FGL1 Protein, Fc Tag
FG1-H82F4 Human Biotinylated FGL1 Protein, Avitag™, Fc Tag
FG1-C5269 Cynomolgus / Rhesus macaque FGL1 Protein, Fc Tag
FG1-H82Ey Human Biotinylated FGL1 Protein, His, Avitag™

FGL1被鉴定为LAG-3的主要配体,如果您同时对LAG-3感兴趣,可以点击获得更多LAG-3产品的相关信息。

活性验证
FGL1的生物活性经Cell-based assay/ BLI/ ELISA验证

Immobilized Human LAG-3, Mouse IgG2a Fc Tag (Cat. No. LA3-H52Aa) at 10 μg/mL (100 μL/well) can bind Human FGL1, Fc Tag (Cat. No. FG1-H5258) with a linear range of 0.02-0.156 μg/mL.

Protocol

Serial dilutions of Anti-LAG3, Neutralizing Antibody were added into Human FGL1, Fc Tag (Cat. No. FG1-H5258): Biotinylated Human LAG-3, Mouse IgG2a Fc,Avitag (Cat. No. LA3-H82F3) binding reactions. The half maximal inhibitory concentration (IC50) is 0.42303 μg/mL.

Protocol

FACS assay shows that Human FGL1, His Tag (Cat. No. FG1-H52Hy) can bind to 293T cells overexpressing human LAG3. The concentration of Human FGL1 is 20 μg/mL.

Protocol

Loaded Human LAG-3, Fc Tag (Cat. No. LA3-H5255) on Protein A Biosensor, can bind Human FGL1, His Tag (Cat. No. FG1-H52Hy) with an affinity constant of 13.6 nM as determined in BLI assay (ForteBio Octet Red96e).

Protocol

*如果您希望ACRO补充更多FGL1产品的实验设计和应用数据,请 点击咨询

*如果您对ACRO有新品开发建议或者对FGL1蛋白有增项建议,请点击 开发建议

消息提示

请输入您的联系方式,再点击提交!

确定